Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
for Systemic Lupus Erythematosus
Drug: Ianalumab
21 locations incl. Anniston
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 12 - 100
Code: NCT06133972·Phase 3·Recruiting